<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6667">
  <stage>Registered</stage>
  <submitdate>24/04/2017</submitdate>
  <approvaldate>24/04/2017</approvaldate>
  <nctid>NCT03142191</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis</studytitle>
    <scientifictitle>A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, Followed by a 28-Week Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-003473-17</secondaryid>
    <secondaryid>CC-90001-IPF-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Pulmonary Fibrosis</healthcondition>
    <healthcondition>Fibrosis</healthcondition>
    <healthcondition>Idiopathic Interstitial Pneumonias</healthcondition>
    <healthcondition>Pathologic Processes</healthcondition>
    <healthcondition>Lung Diseases, Interstitial</healthcondition>
    <healthcondition>Lung Diseases</healthcondition>
    <healthcondition>Respiratory Tract Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CC-90001
Other interventions - Placebo

Experimental: CC-90001 400 mg PO QD - 45 subjects will be randomized to CC-90001 400mg

Experimental: CC-90001 200 mg PO QD - 45 subjects will be randomized to CC-90001 200mg

Placebo Comparator: Placebo PO QD - 45 subjects will be randomized to placebo


Treatment: drugs: CC-90001
CC-90001 is a potent, selective inhibitor of JNK.

Other interventions: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage point change in % predicted Forced vital capacity (FVC) - Mean change from Baseline of percent predicted FVC value between either active treatment group and the placebo group.</outcome>
      <timepoint>Up to approximately 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change and rate of decline in FVC - Absolute change and rate of decline in FVC (expressed in mL) from baseline through Week 24</outcome>
      <timepoint>Up to approximately 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6-minute Walk Test (6MWT) with Borg Scale - Change in the distance walked during the 6MWT as measured in meters (m)</outcome>
      <timepoint>Up to approximately 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Progression - Time to disease progression</outcome>
      <timepoint>Up to approximately 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life - Saint George's Respiratory - The SGRQ is a quality of life health questionnaire that has been validated in IPF. It consists of 76 items in three domains:
Symptoms
Activity
Impact of disease on daily life.</outcome>
      <timepoint>Up to approximately 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life- University of California San Diego Shortness of Breath Questionnaire (UCSD- SOBQ) - The UCSD-SOBQ is a 24-item dyspnea questionnaire that asks subjects to rate themselves from 0 ("Not at all") to 5 ("Maximally or unable to do because of breathlessness") in two areas: 1) how short of breath they are while performing various activities (21 items); and 2) how much shortness of breath, fear of hurting themselves by overexerting, and fear of shortness of breath limit them in their daily lives (3 items).</outcome>
      <timepoint>Up to approximately 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events (AEs) - Type, frequency, severity, and relationship of AEs, clinical laboratory tests including urine cytology, 12-lead ECG, vital signs, and physical examination</outcome>
      <timepoint>Up to approximately 56 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Borg Scale - This is a scale that asks you to rate the difficulty of your breathing. It starts at number 0 where your breathing is causing you no difficulty at all and progresses through to number 10 where your breathing difficulty is maximal. How much difficulty is your breathing causing you right now?</outcome>
      <timepoint>Up to approximately 52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects must satisfy the following criteria to be enrolled in the study:

          1. Subject understands and has voluntarily signed and dated an informed consent form

          2. Subject is male or female = 40 years of age

          3. Subject was diagnosed with IPF within 4 years of Screening

          4. Diagnosis of IPF is supported by HRCT and historical surgical lung biopsy (SLB) if
             available according to guidelines.

          5. No features supporting an alternative diagnosis on transbronchial biopsy,
             bronchoalveolar lavage (BAL), or SLB, if performed.

          6. Percent predicted forced vital capacity (% FVC) = 45% at Screening

          7. Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) = 25% and
             = 85% predicted at Screening.

          8. Able to walk = 150 meters during the 6-minute walk test (6MWT) at Screening

          9. Females of childbearing potential (FCBP) must commit to true abstinence or agree to
             use two effective birth control methods.

         10. Male subjects must practice true abstinence or use a barrier method of contraception.

         11. Additional inclusion criteria apply.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The presence of any of the following will exclude a subject from enrollment:

          1. Subject has any significant medical condition, laboratory abnormality, or psychiatric
             illness that would prevent the subject from participating in the study.

          2. Subject with a QTc calculation using Fridericia's formula (QTcF) &gt; 450 msec.

          3. Evidence of clinically relevant airways obstruction at Screening.

          4. Subjects using any therapy targeted to treat Idiopathic pulmonary fibrosis (IPF).

          5. Use of = 15 hours of supplemental oxygen per day or resting arterial oxygen saturation
             by pulse oximetry (SpO2) of &lt; 92% (room air at sea level) or resting SpO2 of &lt; 88%
             (room air at = 5000 feet [1524 meters] above sea level).

          6. Pregnancy or lactation.

          7. Additional exclusion criteria apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>26/07/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>135</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>13/08/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <hospital>Institute for Respiratory Health Inc - Nedlands</hospital>
    <hospital>St Vincent Hospital - Sydney - Darlinghurst</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6150 - Murdoch</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Santo Andre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Barranquilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogot√°</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Floridablanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Medellin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Chemnitz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Greifenstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wangen im Allgaeu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Alexandroupolis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Haidari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Iraklio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kemerovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Dalin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei, Zhongzheng Dist.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bornova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bursa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Huntingdon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool (Walton Centre)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Norwich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southhampton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Westbury-on-Trym/ Bristol</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Celgene</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled
      study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory
      pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with
      placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis
      (IPF). This study is designed to assess response to treatment by using measures of lung
      function, disease progression, fibrosis on radiography, and patient-reported outcomes. It
      will also assess dose response.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03142191</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Steven Greenberg, M.D</name>
      <address>Celgene</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Associate Director Clinical Trial Disclosure</name>
      <address />
      <phone>1-888-260-1599</phone>
      <fax />
      <email>clinicaltrialdisclosure@celgene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>